Ovarian Cancer

Niraparib (Zejula) met the primary endpoint of overall response as a fourth-line or later treatment in patients with ovarian cancer, regardless of BRCA status, according to top-line results from the QUADRA study.

Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses surgical options for the treatment of patients with newly-diagnosed ovarian cancer.

Bradley J. Monk, MD, professor and director, Division of Gynecologic Oncology, Creighton University School of Medicine, Arizona Oncology, discusses combination approaches in patients with ovarian cancer.

Mike Janicek, MD, medical director, Division of Genetics, Arizona Oncology, discusses the use of genetic testing in patients with ovarian cancer.

An oncologist-led BRCA mutation testing pathway in the ENGAGE study has led researchers to conclude that pretest counseling by the oncology team could shorten testing turnaround times and ease the pressure on genetic counselors.

Lyndsay J. Willmott, MD, gynecologic oncologist, Arizona Oncology, discusses the mechanisms of resistance to PARP inhibitors that have been identified in ovarian cancer.

Dennis R. Scribner, MD, FACOG, FACS, clinical associate professor for the University of Arizona School of Medicine, Arizona Oncology, discusses the use of chemotherapy in patients with ovarian cancer.

Mike Janicek, MD, medical director, Genetics Division, Arizona Oncology, discusses progress with genetic testing in ovarian cancer.

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses the standard of care for patients with ovarian cancer.

Bradley J. Monk, MD, FACOG, FACS, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Arizona Oncology, discusses the FDA approval of rucaparib (Rubraca) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

David O'Malley, MD, gynecologic oncologist and an assistant professor in the Department of Obstetrics and Gynecology at The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of rucaparib (Rubraca)

The FDA has approved rucaparib for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses determining the management strategy for patients with ovarian cancer.

Michael Birrer, MD, PhD, discusses the effect that PARP inhibitors have had on the treatment of ovarian cancer, and the potential for combinations with these agents.

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses the impact of PARP inhibitors in ovarian cancer.

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

First-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab, followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.